Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Treasury Shares (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Treasury Shares for 5 consecutive years, with $3.0 million as the latest value for Q1 2026.

  • For Q1 2026, Treasury Shares rose 15642410.53% year-over-year to $3.0 million; the TTM value through Mar 2026 reached $3.0 million, up 15642410.53%, while the annual FY2025 figure was $19.0, 0.0% changed from the prior year.
  • Treasury Shares hit $3.0 million in Q1 2026 for Phathom Pharmaceuticals, up from $19.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $3.0 million in Q1 2026 and bottomed at $19.0 in Q1 2022.
  • Average Treasury Shares over 5 years is $638208.5, with a median of $19.0 recorded in 2022.
  • Year-over-year, Treasury Shares changed 0.0% in 2023 and then surged 15642410.53% in 2026.
  • Phathom Pharmaceuticals' Treasury Shares stood at $19.0 in 2022, then changed by 0.0% to $19.0 in 2023, then changed by 0.0% to $19.0 in 2024, then changed by 0.0% to $19.0 in 2025, then soared by 15642410.53% to $3.0 million in 2026.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $3.0 million, $19.0, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.